Not Yet Recruiting

NCT Number: NCT07487155

Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Attention Deficit Disorder With Hyperactivity (ADHD) Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Chemically-Induced Disorders Mental Disorders Neurodevelopmental Disorders Substance Use Disorder (SUD) Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Brest

Brest, 29200, France

Location contact

Morgane GUILLOU LANDREAT, MD

CONTACT

[email protected]

029822342348

Morgane GUILLOU LANDREAT, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult, under the supervision of the justice system or monitored by a correctional facility
Diagnosis of Substance Use Disorder (SUD)
Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
No objection from the patient
Affiliated with a Social Security system

Exclusion criteria

Severe or decompensated psychiatric disorders
Severe cognitive impairment
Lack of understanding of the French language
Refusal to participate

Treatment and study plan

Workshop

Other

Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study

Primary outcomes

80% of patients participated in the workshops

Time frame: From enrollment to the end of wordshop at 6 months
The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through:
- Semi-structured pre- and post-intervention interviews
- A Likert scale
- Workshop participation rate (at least 80%)

Secondary outcomes

SF-12 quality of life

Time frame: From enrollment to the end of wordshop at 6 months

The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.

Study contacts

Contact information is provided by the study sponsor or research team.

Marie BARAIS, MD

CONTACT

[email protected]

+332 98 01 64 02

Tiphaine MENEZ

CONTACT

[email protected]

+33230338460

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: JUSTICE-TDAH

Important dates

Study start: 2026
Primary completion: 2028
Study completion: 2028
First posted: Mar 23, 2026
Registry last updated: Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting